Phase 3 Start
AZN: Phase3_Start: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Baxdrostat on Ambulatory Blood Pressure in Chinese Participants With Uncontrolled Hypertension on Two or More Antihypertensive Medications Without Diuretics
September 30, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 30, 2026
- Company
- ASTRAZENECA PLC (AZN)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Start
Phase3_Start: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Baxdrostat on Ambulatory Blood Pressure in Chinese Participants With Uncontrolled Hypertension on Two or More Antihypertensive Medications Without Diuretics
- Company
- ASTRAZENECA PLC (AZN)
Other upcoming events for AZN
Phase 3 StartPhase3_Start: A Randomized, Double-Blind, Placebo-Controlled, 2-Cohort, Phase III Study of Saruparib Combined With Physician's Choice of Androgen Receptor Pathway Inhibitor in Patients With Metastatic Hormone-Sensitive Prostate Cancer, Previously Treated With Docetaxel or PSMA-directed 177Lutetium-Containing Therapy Without Disease Progression, and With Prostate-Specific Antigen ≥ 0.2 ng/mL: EvoPAR-Prostate05
Phase 1 StartPhase1_Start: A Multicentre, Randomised, Open-label, Phase I Study to Characterise the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Administered Subcutaneously or Intravenously in Participants With Systemic Lupus Erythematosus